These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 11514474)
1. Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond. Manoharan G; Adgey AA Heart; 2001 Sep; 86(3):259-61. PubMed ID: 11514474 [No Abstract] [Full Text] [Related]
2. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. Kleiman NS; Lincoff AM; Ohman EM; Harrington RA Am Heart J; 1998 Oct; 136(4 Pt 2 Su):S32-42. PubMed ID: 9778086 [TBL] [Abstract][Full Text] [Related]
3. [Use of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndrome and coronary intervention]. Kakuta T; Kishi Y; Numano F Nihon Rinsho; 1998 Oct; 56(10):2630-4. PubMed ID: 9796330 [TBL] [Abstract][Full Text] [Related]
4. Contemporary view of the acute coronary syndromes. Moustapha A; Anderson HV J Invasive Cardiol; 2003 Feb; 15(2):71-9. PubMed ID: 12556619 [No Abstract] [Full Text] [Related]
6. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. Antman EM Am Heart J; 2003 Oct; 146(4 Suppl):S18-22. PubMed ID: 14564302 [TBL] [Abstract][Full Text] [Related]
7. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697 [TBL] [Abstract][Full Text] [Related]
12. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Fernandez JS; Sadaniantz A Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658 [No Abstract] [Full Text] [Related]
13. Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes. Elmouchi DA; Bates ER Minerva Cardioangiol; 2003 Oct; 51(5):547-60. PubMed ID: 14551523 [TBL] [Abstract][Full Text] [Related]
14. Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions. Mahaffey KW; Harrington RA JAMA; 2007 Feb; 297(6):636-9. PubMed ID: 17299199 [No Abstract] [Full Text] [Related]
15. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519 [TBL] [Abstract][Full Text] [Related]
16. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years? Silva MA; Gandhi PJ J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937 [TBL] [Abstract][Full Text] [Related]
17. Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Subbarao VD; Phillips J; Stouffer GA Am J Med Sci; 1999 Aug; 318(2):107-14. PubMed ID: 10452570 [TBL] [Abstract][Full Text] [Related]
18. Acute coronary syndrome: are intervention and IIb/IIIa platelet inhibitors epiphenomena? Jackson G Int J Clin Pract; 2001; 55(6):351-2. PubMed ID: 11501219 [No Abstract] [Full Text] [Related]